Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $21.59, for a total transaction of $70,167.50. Following the transaction, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at approximately $280,670. This represents a 20.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total transaction of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total transaction of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.89, for a total transaction of $130,672.50.

Enliven Therapeutics Trading Down 0.9 %

Shares of NASDAQ:ELVN traded down $0.18 during mid-day trading on Wednesday, reaching $20.86. The stock had a trading volume of 326,656 shares, compared to its average volume of 275,742. The firm has a market cap of $1.02 billion, a PE ratio of -10.98 and a beta of 1.04. The firm has a 50 day simple moving average of $23.27 and a two-hundred day simple moving average of $24.33. Enliven Therapeutics, Inc. has a twelve month low of $10.90 and a twelve month high of $30.03.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently made changes to their positions in the business. American Century Companies Inc. lifted its holdings in shares of Enliven Therapeutics by 44.7% during the second quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after buying an additional 8,540 shares in the last quarter. Marshall Wace LLP acquired a new position in Enliven Therapeutics in the second quarter valued at approximately $4,489,000. The Manufacturers Life Insurance Company bought a new position in shares of Enliven Therapeutics in the second quarter valued at $322,000. SG Americas Securities LLC purchased a new stake in shares of Enliven Therapeutics in the third quarter valued at about $256,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after buying an additional 3,559 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ELVN. Robert W. Baird boosted their price objective on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. BTIG Research started coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They set a “buy” rating and a $42.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Enliven Therapeutics presently has an average rating of “Buy” and an average target price of $38.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.